{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+capsules&page=4",
    "query": {
      "intervention": "Placebo capsules",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 4731,
    "total_pages": 474,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+capsules&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+capsules&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T17:08:00.098Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05571059",
      "title": "Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Ifetroban Sodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2024-01-31",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-17T17:08:00.098Z",
      "location_count": 20,
      "location_summary": "La Mesa, California • San Francisco, California • Farmington, Connecticut + 17 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05571059"
    },
    {
      "nct_id": "NCT07717879",
      "title": "Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Solriamfetol Dose A",
          "type": "DRUG"
        },
        {
          "name": "Solriamfetol Dose B",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Axsome Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 468,
      "start_date": "2026-07-06",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-17T17:08:00.098Z",
      "location_count": 30,
      "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 26 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07717879"
    },
    {
      "nct_id": "NCT05084196",
      "title": "Melatonin for Prevention of Kidney Injury",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Kidney Injury",
        "Adverse Drug Event"
      ],
      "interventions": [
        {
          "name": "Melatonin",
          "type": "DRUG"
        },
        {
          "name": "Placebo Capsule",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 300,
      "start_date": "2023-06-05",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-10-17T17:08:00.098Z",
      "location_count": 2,
      "location_summary": "New Brunswick, New Jersey • Somerville, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Somerville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05084196"
    },
    {
      "nct_id": "NCT00224120",
      "title": "A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Benign Prostatic Hyperplasia"
      ],
      "interventions": [
        {
          "name": "Silodosin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Watson Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "50 Years and older · Male only"
      },
      "enrollment_count": 462,
      "start_date": "2005-05",
      "completion_date": "2006-05",
      "has_results": true,
      "last_update_posted_date": "2009-12-15",
      "last_synced_at": "2026-10-17T17:08:00.098Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Carmichael, California • Fresno, California + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Laguna Woods",
          "state": "California"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00224120"
    },
    {
      "nct_id": "NCT03203915",
      "title": "Metabolic Response to Chardonnay Grape Marc Powder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dyslipidemia",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Chardonnay grape marc marc high polyphenol dose (120mg)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Chardonnay grape marc powder low polyphenol dose (75mg)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo (0mg)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "USDA, Western Human Nutrition Research Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 31,
      "start_date": "2017-08-01",
      "completion_date": "2019-06-28",
      "has_results": false,
      "last_update_posted_date": "2021-07-16",
      "last_synced_at": "2026-10-17T17:08:00.098Z",
      "location_count": 1,
      "location_summary": "Davis, California",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03203915"
    },
    {
      "nct_id": "NCT01082640",
      "title": "Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "Febuxostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2010-04",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2013-09-25",
      "last_synced_at": "2026-10-17T17:08:00.098Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Peoria, Arizona • Sierra Vista, Arizona + 55 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Sierra Vista",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01082640"
    },
    {
      "nct_id": "NCT04781140",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "100mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "48 Months",
        "maximum_age": "69 Months",
        "sex": "ALL",
        "summary": "48 Months to 69 Months"
      },
      "enrollment_count": 286,
      "start_date": "2024-03-19",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-17T17:08:00.098Z",
      "location_count": 54,
      "location_summary": "Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more",
      "locations": [
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04781140"
    },
    {
      "nct_id": "NCT03014323",
      "title": "Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insulin Sensitivity",
        "Oxidative Stress"
      ],
      "interventions": [
        {
          "name": "Galantamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2017-01",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2018-08-13",
      "last_synced_at": "2026-10-17T17:08:00.098Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03014323"
    },
    {
      "nct_id": "NCT05878522",
      "title": "A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "sisunatovir",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 43,
      "start_date": "2023-05-15",
      "completion_date": "2023-10-30",
      "has_results": true,
      "last_update_posted_date": "2024-12-06",
      "last_synced_at": "2026-10-17T17:08:00.098Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05878522"
    },
    {
      "nct_id": "NCT01896531",
      "title": "A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2013-08-14",
      "completion_date": "2021-01-26",
      "has_results": true,
      "last_update_posted_date": "2022-03-02",
      "last_synced_at": "2026-10-17T17:08:00.098Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01896531"
    }
  ]
}